Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 10/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254801 | 0.85 | KMT2A (0.44) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL2398699 | 0.84 | GPR183 (0.57) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL2399002 | 0.84 | HRH4 (0.53) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL2401624 | 0.82 | HRH4 (0.56) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL3252827 | 0.76 | AVPR1A (0.52) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL3252765 | 0.72 | HRH4 (0.58) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL3255524 | 0.72 | HRH4 (0.58) | HRH4HRH3GPR183KMT2ADRD3 | |
| SCHEMBL3252816 | 0.72 | HRH4 (0.55) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL4983490 | 0.72 | HRH4 (0.55) | HRH4HRH3GPR183KMT2AMEN1 | |
| SCHEMBL2398151 | 0.71 | HRH4 (0.56) | HRH4HRH3GPR183KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022213-B2 | 6'-Bromo-1-[(5-methoxy-3-methyl-1H-indol-2-yl)carbonyl]-1'H-spiro[piperidine-4,4'-quinolin]-2'(3'H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022213-B2 | 6'-Bromo-1-[(5-methoxy-3-methyl-1H-indol-2-yl)carbonyl]-1'H-spiro[piperidine-4,4'-quinolin]-2'(3'H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022213-B2 | 6'-Bromo-1-[(5-methoxy-3-methyl-1H-indol-2-yl)carbonyl]-1'H-spiro[piperidine-4,4'-quinolin]-2'(3'H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7432259-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432259-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432259-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080161298-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161298-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161298-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161299-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161299-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161299-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008068159-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161299-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HRH4 211/4885HRH3 455/4885GPR183 408/4885 |
| US-20080161298-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HRH4 211/4885HRH3 455/4885GPR183 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.